# Linkinvax Europe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/linkinvax-europe

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.linkinvax.com
- Total disclosed funding: $53M
- Latest round: Series A (Jan 9, 2023)
- Investors on record: 1

## About

Based in Paris, France, and founded in 2020 by its CEO, Dr. Auberton-Hervé André-Jacques, and co-founders Gaston-Dreyfus Rémi, and Pr. Yves Lévy, Linkinvax Europe operates as a clinical-stage biotechnology company that specializes in the research and development of prophylactic and therapeutic vaccines. In January 2023, Linkinvax Europe raised EUR 50 million in series A funding from In-Q-Tel, with participation from the company's management. 

Linkinvax Europe offers a protein-based vaccine platform that addresses multiple pathogens with adaptability to mutations, including viral or bacterial infectious diseases and cancer treatments. Its product portfolio encompasses a wide range of dendritic cell-based vaccines, both preventive and therapeutic, such as the COVID-19 vaccine, developed to address multi-epitopes and variants, as well as the pandemic caused by the SARS-CoV-2 virus; the HIV vaccine; and the HPV-linked cancer vaccine. 

The company plans to use the Series A funding to accelerate the clinical development of its protein-based vaccine platform.

## Funding rounds

- Series A, Jan 9, 2023, $53M — In-Q-Tel

## Investors

- In-Q-Tel (https://capitalatlas.ai/funds/in-q-tel) — Series A